Bio-Rad Laboratories (BIO)
NYSE:BIO
Want to see BIO full AI Analyst Report?
Top Page
Bio-Rad Laboratories
(NYSE:BIO)
Select Model
Select Model
Rating:66Neutral
Price Target:
$304.00
▲(1.67% Upside)
Action:Reiterated
Date:05/19/26
The score is primarily supported by strong financial resilience (low leverage, solid margins, and positive cash generation), but is held back by weak technical momentum and a cautious near-term outlook from updated guidance (soft currency-neutral growth range and lowered FCF guidance). Valuation provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Balance sheet strength
Very low leverage (debt ≈0.08x equity) and a return to ~10–11% ROE provide durable financial flexibility. This supports sustained R&D, targeted M&A, and buybacks while helping the company absorb cyclical demand shocks, preserving operational stability over the coming months.
Negative Factors
Cautious revenue guidance
Company guidance showing currency‑neutral revenue of −3% to +0.5% signals persistent demand softness across core end markets. That narrowing-to-negative outlook constrains organic growth visibility and implies possible continued top‑line pressure for several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage (debt ≈0.08x equity) and a return to ~10–11% ROE provide durable financial flexibility. This supports sustained R&D, targeted M&A, and buybacks while helping the company absorb cyclical demand shocks, preserving operational stability over the coming months.
Read all positive factors
Bio-Rad Laboratories Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyBio-Rad Laboratories (BIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.72B
Dividend YieldN/A
Average Volume (3M)394.35K
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue Growth1.92%
EPS GrowthN/A
CountryUS
Employees7,700
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)6.11
Shares Outstanding21,700,560
10 Day Avg. Volume485,231
30 Day Avg. Volume394,351
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)1.11
Price to Sales (P/S)3.20
P/FCF Ratio22.05
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue3.34
Enterprise Value/Gross Profit6.44
Enterprise Value/Ebitda250.10
Forecast
1Y Price Target
$296.25Price Target Upside-0.93% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)9.17
Revenue Forecast (FY)$2.58B
Bio-Rad Laboratories Business Overview & Revenue Model
Company Description
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segme...
How the Company Makes Money
Bio-Rad makes money primarily by selling laboratory products and related services across two main operating segments: Life Science and Clinical Diagnostics. In Life Science, revenue is generated from sales of research instruments (e.g., analytical...
Bio-Rad Laboratories Earnings Call Summary
Earnings Call Date:Apr 30, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Negative
The call presented a mix of operational and commercial progress (notably strong ddPCR instrument growth, strategic initiatives, solid liquidity and ongoing buybacks) but was dominated by near-term headwinds: meaningful currency‑neutral revenue declines, geopolitical disruption in the Middle East (an $11M Q1 impact and ongoing drag), margin pressure, weaker consumable pull‑through, and a material reported loss driven by the Sartorius mark‑to‑market adjustment. Management is pursuing cost and operational actions and adjusted full‑year guidance reflects a cautious near‑term outlook.Positive Updates
Reported Revenue Slightly Higher
Net sales of approximately $592 million in Q1 2026, a 1.1% increase on a reported basis versus $585 million in Q1 2025 (currency-neutral: -4.2% YoY).
Negative Updates
Currency-Neutral Revenue Decline and Lower Full-Year Guidance
Currency-neutral revenue decreased 4.2% YoY in Q1. Updated 2026 non‑GAAP guidance calls for currency-neutral revenue growth of -3.0% to +0.5% for the full year, with Life Science expected -3% to -1% and Diagnostics -3% to +1%.
Read all updates
Q1-2026 Updates
Positive
Negative
Reported Revenue Slightly Higher
Net sales of approximately $592 million in Q1 2026, a 1.1% increase on a reported basis versus $585 million in Q1 2025 (currency-neutral: -4.2% YoY).
Read all positive updates
Company Guidance
Bio‑Rad updated 2026 non‑GAAP guidance to currency‑neutral revenue growth of −3% to +0.5% (Life Science −3% to −1%; Diagnostics −3% to +1%), with quality controls expected to grow mid‑single‑digits while Diagnostics ex‑quality controls is expected to decline mid‑ to low‑single‑digits; Life Science also bears a high‑single‑digit‑million adverse impact from the Middle East. Full‑year non‑GAAP gross margin is forecast at 53%–54%, non‑GAAP operating margin at 10%–12%, and the non‑GAAP tax rate at ~22%; free cash flow is now guided to ~$290M–$340M. The company noted an $11M Q1 hit from the Middle East, reported Q1 sales of about $592M (reported +1.1%, FX‑neutral −4.2%), Q1 non‑GAAP net income of $51M (diluted EPS $1.89), repurchased 176k shares for ~$48M in Q1 and has ≈$237M available under its buyback authorization.Bio-Rad Laboratories Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
86
Very Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.59B | 2.58B | 2.57B | 2.67B | 2.80B | 2.92B |
| Gross Profit | 1.34B | 1.34B | 1.38B | 1.43B | 1.57B | 1.64B |
| EBITDA | 34.60M | 475.90M | -2.14B | -654.80M | -4.49B | 5.59B |
| Net Income | 168.80M | 759.90M | -1.84B | -637.32M | -3.63B | 4.25B |
Balance Sheet | ||||||
| Total Assets | 9.79B | 10.58B | 9.36B | 12.30B | 13.50B | 17.80B |
| Cash, Cash Equivalents and Short-Term Investments | 1.56B | 1.54B | 1.66B | 1.61B | 1.79B | 869.92M |
| Total Debt | 1.38B | 1.53B | 1.37B | 1.41B | 1.39B | 223.38M |
| Total Liabilities | 2.94B | 3.12B | 2.79B | 3.56B | 3.89B | 4.11B |
| Stockholders Equity | 6.85B | 7.45B | 6.57B | 8.74B | 9.62B | 13.69B |
Cash Flow | ||||||
| Free Cash Flow | 357.20M | 374.60M | 266.20M | 218.26M | 80.29M | 535.72M |
| Operating Cash Flow | 510.40M | 532.20M | 455.20M | 374.94M | 194.45M | 669.46M |
| Investing Cash Flow | -285.80M | -189.70M | -160.20M | 20.21M | -1.21B | -797.38M |
| Financing Cash Flow | -229.50M | -283.20M | -218.80M | -425.65M | 973.58M | -55.43M |
Bio-Rad Laboratories Technical Analysis
Positive
299.02
Price Trends
273.21
Positive
284.19
Positive
292.49
Negative
Market Momentum
-2.46
Negative
61.66
Neutral
95.55
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIO, the sentiment is Positive. The current price of 299.02 is above the 20-day moving average (MA) of 265.34, above the 50-day MA of 273.21, and above the 200-day MA of 292.49, indicating a neutral trend. The MACD of -2.46 indicates Negative momentum. The RSI at 61.66 is Neutral, neither overbought nor oversold. The STOCH value of 95.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIO.
Bio-Rad Laboratories Risk Analysis
Bio-Rad Laboratories disclosed 28 risk factors in its most recent earnings report. Bio-Rad Laboratories reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bio-Rad Laboratories Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $27.57B | 30.31 | 33.83% | ― | 16.15% | 76.15% | |
72 Outperform | $47.77B | 30.46 | 10.55% | ― | 13.81% | 22.90% | |
68 Neutral | $84.23B | 17.42 | 14.82% | ― | 17.44% | 74.36% | |
67 Neutral | $100.34B | 28.29 | 9.54% | 2.76% | 6.88% | 9.06% | |
66 Neutral | $7.72B | -3.56 | 2.40% | ― | 1.92% | ― | |
62 Neutral | $25.37B | 31.92 | 8.96% | 3.30% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
BIO
Bio-Rad Laboratories
287.86
59.88
26.27%
BSX
Boston Scientific
56.67
-47.97
-45.84%
DXCM
Dexcom
71.44
-13.45
-15.84%
EW
Edwards Lifesciences
82.97
6.87
9.03%
PHG
Koninklijke Philips
26.74
4.06
17.89%
MDT
Medtronic
78.15
-3.66
-4.47%
Bio-Rad Laboratories Corporate Events
Business Operations and StrategyStock BuybackFinancial Disclosures
Bio-Rad Laboratories Reports Q1 2026 Results, Cuts Outlook
Negative
Apr 30, 2026
Bio-Rad Laboratories reported first-quarter 2026 results on April 30, 2026, showing total net sales of $592.1 million, up 1.1% year-on-year, but a 4.2% decline on a currency-neutral basis, with softness across both Life Science and Clinical Diagno...
Executive/Board ChangesShareholder Meetings
Bio-Rad Laboratories Stockholders Approve Directors and Governance Items
Positive
Apr 24, 2026
At its April 21, 2026 annual meeting of stockholders, Bio-Rad Laboratories, Inc. reported that all nominated directors were elected by majorities within their respective classes of common stock, reinforcing continuity in the company’s board ...
Business Operations and StrategyFinancial Disclosures
Bio-Rad Updates Investors on Sartorius Strategic Investment Metrics
Positive
Feb 19, 2026
Bio-Rad Laboratories provided an update on February 16, 2026, regarding its investment in Sartorius AG by disclosing selected 2025 financial metrics reported by Sartorius. For the year ended December 31, 2025, Sartorius posted €3.54 billion ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.